A Japanese female patient with angioimmunoblastic T cell lymphoma underwent allogeneic bone marrow transplantation (BMT) from her brother. Cyclosporine at a dose of 3 mg/kg was started by continuous infusion over 24 h on day −1 of BMT. Within a couple of minutes after the infusion was begun, she developed diffuse pruritic erythema on her whole body and tachycardia. The infusion was immediately stopped and corticosteroid was given, resulting in disappearance of the erythema gradually. She was then switched to intravenous tacrolimus. However, she suffered urticalial erythema again. Since polyoxyethylated castor oil, a solubilizer used in the injective formulation of both cyclosporine and tacrolimus, is considered to be responsible for the reaction, she was given oral capsules of cyclosporine (Sandimmun) in which polyoxyethylated castor oil was not contained. No further anaphylactic reaction was observed. The BM cells were successfully engrafted without causing severe GVHD. She was discharged on cyclosporine capsules without any further adverse effects. Anaphylaxis to intravenous cyclosporine and tacrolimus is a very rare but a serious complication. Our present case indicates that oral capsule of Sandimmun is a safe alternative to prevent GVHD in such a case of anaphylactic reaction against intravenous formulation. Bone Marrow Transplantation (2001) 28, 421-423. Keywords: anaphylaxis; cyclosporine; tacrolimus Cyclosporine has been widely used to prevent graft-versushost disease (GVHD) in allogeneic bone marrow transplantation (BMT) as well as to allow engraftment of transplanted organs including kidney, liver and heart allografts. ever, once anaphylaxis has occurred in a BMT recipient, another immunosuppressive agent is needed since high-dose chemotherapy with or without total body irradiation has been already given prior to the start of cyclosporine, for GVHD prophylaxis. Tacrolimus is an alternative agent often used for the treatment of GVHD when cyclosporine is not effective. Here, we report a patient who developed anaphylaxis to both intravenous cyclosporine and tacrolimus but who tolerated oral cyclosporine in capsule form.
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A 45-year-old Japanese woman with angioimmunoblastic T cell lymphoma was admitted for allogeneic BMT from her HLA-identical brother. She had had no history of drug allergy while she received anti-neoplastic chemotherapy for 8 months. Following 2 Gy of total body irradiation once daily for 3 consecutive days (total 6 Gy) and the intravenous administration of cytarabine 1 g/m 2 twice daily for 2 days and cyclophosphamide 50 mg/kg once daily for 2 days, she started cyclosporine 1 day prior to BMT. Cyclosporine at a dose of 3 mg/kg was mixed in 500 ml of 5% glucose solution for continuous 24 h infusion. A couple of minutes after the start of the infusion, she developed diffuse pruritic erythema with wheals on her extremities, trunk and face. Her pulse rate increased to 110/min but the blood pressure and respiratory rate did not alter. The infusion was immediately stopped and corticosteroid given. Since the erythema gradually disappeared after the cessation of the cyclosporine and all other drugs were continued without subsequent reactions, it was considered that the erythema was caused by an anaphylactic reaction to cyclosporine. She was then switched to tacrolimus 0.03 mg/kg by continuous i.v. infusion over 24 h. However, the pruritic erythema re-appeared on her face and extremities within half an hour. The intravenous tacrolimus was discontinued, and the erythema disappeared spontaneously. This patient experienced anaphylaxis to both intravenous cyclosporine and tacrorimus, suggesting that the anaphylaxis was not due to either cyclosporine or tacrolimus themselves but rather to the polyoxyethylated castor oil which was the vehicle in which these two drugs were dissolved. We therefore administered an oral capsule formulation of cyclosporine (Sandimmun; Novartis Pharma KK, Tokyo, Japan) because this agent does not contain polyoxyethylated castor oil. No allergic reaction appeared following the oral cyclosporine treatment. In addition to cyclosporine, methotrexate was given by i.v. infusion at doses of 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6. She received a total of 2 × 10 8 /kg of bone marrow mononuclear cells which were harvested from her brother, followed by successful hemopoietic recovery, defined as leukocyte recovery to Ͼ1 × 10 9 /l and platelet recovery to Ͼ5 × 10 9 /l on day 17. The subsequent post-transplant course was uneventful until day 28 when a maculopapular exanthema appeared on her cheeks, upper extremities and back (Ͻ25% of body surface). Neither hyperbilirubinemia nor diarrhea was observed, indicating that she had grade I acute GVHD. Since the exanthema was self-limited, she received no further treatment. The karyotype of bone marrow cells analyzed by FISH on day 30 showed that 99% of the cells were of donor origin, indicating successful engraftment. She was discharged on day 45 taking cyclosporine 300 mg daily.
Anaphylaxis to intravenous cyclosporine was first described in a renal transplant recipient in whom hypotension and dyspnea developed immediately after the start of intravenous cyclosporine and disappeared within 30 min after discontinuation of the infusion. 2 Anaphylaxis was fatal in a patient who received intravenous cyclosporine for liver transplantation which resulted in cardiopulmonary arrest. 3 Polyoxyethylated castor oil, a solubilizer used in the injection formulation of cyclosporine, is thought to be responsible for the anaphylaxis, because similar anaphylactic reactions have been observed after treatment with other drugs containing polyoxyethylated castor oil, such as paclitaxel, multivitamin hydrosol and vitamin K. [4] [5] [6] When cyclosporine causes complications such as neurological problems or nephrotoxicity, switching from cyclosporine to tacrolimus is recommended. 7 However, the present case developed an anaphylactic reaction to intravenous tacrolimus as well as to cyclosporine. Polyoxyethylated castor oil is also used as a vehicle for tacrolimus, indicating that intravenous tacrolimus is contraindicated in cases of cyclosporine-associated anaphylaxis. This patient has taken the oral capsule formulation of cyclosporine (Sandimmun), which does not contain polyoxyethylated castor oil, for 3 months without developing either anaphylaxis or severe GVHD. There are similar reports in which patients who developed anaphylaxis to intravenous cyclosporine were tolerant of oral cyclosporine capsules. [8] [9] [10] [11] There is another oral capsule formulation of cyclosporine named Neoral (Novartis Pharma). Neoral has the advantage of better absorption from the gut when compared with Sandimmun. However, the safety of Neoral is unclear in the intravenous cyclosporine-associated anaphylaxis setting because Neoral contains a polyoxyethylated castor oil derivative and a case of anaphylaxis after ingestion of oral Neoral has been reported. 12 Besides the oral capsule, an oral solution of cyclosporine (Sandimmun) is commercially available. Although it contains no castol oil but rather an olive oil derivative, there are reports describing anaphylaxis to the oral liquid formulation but no reaction to the oral capsule. 8, 9 It suggests that oral Sandimmun capsules are the treatment of choice when patients have anaphylaxis with intravenous cyclosporine.
A high incidence of anaphylaxis has been reported in a pharmacokinetic study of cyclosporine. 13 Five of six healthy males who received 190 mg of cyclosporine intravenously experienced anaphylactic reactions. However, anaphylactic reactions to intravenous cyclosporine have been described in only four cases after BMT 10, 11, 14, 15 and in eight cases of organ transplantation, 2, 3, 9, [16] [17] [18] suggesting that the incidence of anaphylactic reactions to cyclosporine is very low in BMT and organ transplant recipients. Prophylactic anti-allergic premedication is known to decrease the incidence of anaphylactic reactions to paclitaxel in which polyoxyethylated castor oil is used. 4 It is speculated that high-dose chemotherapy with or without total body irradiation given as conditioning for BMT, and the other immunosuppressive agents such as prednisolone and azathioprine administered together with cyclosporine in organ transplantation induce significant immunosuppression in the host, resulting in relatively rare reactions to cyclosporine.
The present case received a reduced-dose conditioning regimen resulting in very mild mucositis and allowing her to take cyclosporine orally during the whole transplantation course. When recipients are capable of taking oral medications, initiating GVHD prophylaxis with oral Sandimmun capsules can be considered to avoid the risk of anaphylaxis as well as to reduce the cost of transplantation.
